Envoy Medical Inc. (Class A) (COCH) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, Envoy Medical Inc. (Class A) (NASDAQ: COCH) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $6.50 (-2.40% 1D, market cap $50.3M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, COCH ranks #584 in composite RQD confidence.
Within the Health Care sector (Industrial Specialties), COCH carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -35.0%. By comparison, MYO (Myomo Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $51.5M) and APT (Alpha Pro Tech Ltd.) posts a D+ grade (58/100 RQD, P/E 16.2x, ROIC 6.7%, cap $56.6M). Among the 5-stock peer group, APT leads on earnings multiple (16.2x) while APT leads on capital efficiency (6.7% ROIC).
Per COCH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001840877), Envoy Medical Inc. (Class A) generated $241.0K in revenue (+7.1% YoY), -$23.8M in net income, and -$18.4M in free cash flow against $8.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 49% of 52W Range • RSI-14 at 50.8 (NEUTRAL RANGE)
20D Institutional Volume Accumulation (±12.5% realized swing band)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While COCH currently carries a cautious 42/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.86) and Max Pain ($6.83) forces dealer call-delta covering toward $10.02.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Envoy Medical Inc. (Class A) (COCH) dropped -2.40% to $6.50, trading at 49% of its 52-week range ($3.63 – $9.54). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Financial Results to Be Released Before Market OpenWhite Bear Lake, Minnesota--(Newsfile Corp. - October 28, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health and neuroprosth
Management Will Host a Conference Call at 4:30 P.M. ET on the Same DayWhite Bear Lake, Minnesota--(Newsfile Corp. - October 27, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing hea
IQVIA (IQV) delivered earnings and revenue surprises of +3.09% and +1.44%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
White Bear Lake, Minnesota--(Newsfile Corp. - October 22, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health and neuroprosthetics company pioneering fully implanted hearing so
Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health and neuroprosthetics company pioneering fully implanted hearing solutions, today announced that it will implement a
Company Believes It Is the First to Reach This Milestone in a U.S. Pivotal Trial of a Fully Implanted Cochlear ImplantRemains on Track to Reach 12-Month Visit Milestone by Early Q2 2027 and Submit Final Clinical PMA Modu
Company Believes It Is the First to Reach This Milestone in a U.S. Pivotal Trial of a Fully Implanted Cochlear ImplantRemains on Track to Reach 12-Month Visit Milestone by Early Q2 2027 and Submit Final Clinical PMA
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +7.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on COCH today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for COCH. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Envoy Medical Inc. (Class A) (COCH) ranks #584 by composite RQD confidence (42/100, grade D-) and #752 by equity capitalization ($50.3M). Within this direct 5-issuer industry benchmark cohort, APT leads on earnings valuation at 16.2x trailing P/E, while APT leads on capital efficiency and profitability with 6.7% ROIC and 38.1% gross margin. APT currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with COCH at 42/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| COCH
ACTIVE
Envoy Medical Inc. (Class A) | D- | 42/100 | — | -30.0% | -35.0% | -2.40% | $50.3M | Benchmark Subject |
| MYO Myomo Inc. | D- | 37/100 | — | 65.7% | -35.0% | +3.18% | $51.5M | /myo-vs-coch → |
| APT Alpha Pro Tech Ltd. | D+ | 58/100 | 16.2x | 38.1% | 6.7% | +1.28% | $56.6M | /apt-vs-coch → |
| NTRB Nutriband Inc. | D- | 40/100 | — | 27.8% | -35.0% | +3.75% | $80.7M | /ntrb-vs-coch → |
| CNXU Conexeu Sciences Inc. | D+ | 56/100 | — | — | — | -1.74% | $85.8M | /cnxu-vs-coch → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Envoy Medical Inc. (Class A) (COCH) reported GAAP revenue of $241.0K (+7.1% vs. FY2024 revenue of $225.0K , and -23.7% cumulative change since FY2023) , GAAP net income of -$23.8M, operating cash flow of -$18.2M, and free cash flow of -$18.4M (+2.9% YoY). On the balance sheet, COCH closed FY2025 with $8.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $241.0K | -$23.8M | -$18.2M | -$18.4M | $8.6M | — |
| FY2024 (FY) | 2024-12-31 | $225.0K | -$20.8M | -$17.9M | -$18.9M | $11.5M | — |
| FY2023 (FY) | 2023-12-31 | $316.0K | -$29.9M | -$17.1M | -$17.1M | — | — |
As of 2026-11-01, Envoy Medical Inc. (Class A) (NASDAQ: COCH) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $6.50 (-2.40% 1D, market cap $50.3M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, COCH ranks #584 in composite RQD confidence.
Within the Health Care sector (Industrial Specialties), COCH carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -35.0%. By comparison, MYO (Myomo Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $51.5M) and APT (Alpha Pro Tech Ltd.) posts a D+ grade (58/100 RQD, P/E 16.2x, ROIC 6.7%, cap $56.6M). Among the 5-stock peer group, APT leads on earnings multiple (16.2x) while APT leads on capital efficiency (6.7% ROIC).
Per COCH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001840877), Envoy Medical Inc. (Class A) generated $241.0K in revenue (+7.1% YoY), -$23.8M in net income, and -$18.4M in free cash flow against $8.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
COCH last traded at $6.50 (-2.40% on volume of 96,593 shares), positioning the stock -5.25% below its 50-day simple moving average ($6.86) and -5.39% below its 200-day simple moving average ($6.87). Across its 52-week range of $3.63 to $9.54, COCH sits at the 48.6% percentile with a 14-day RSI of 50.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($5.69 to $7.31).
Why COCH Stock dropped -2.40% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.